Weight Management Strategies in Obesity and Diabetes

Obesity and type 2 diabetes represent interlinked epidemics with profound global health consequences. Effective weight management can prevent onset of diabetes, improve glycaemic control and reduce cardiovascular risk. Strategies encompass lifestyle modification, pharmacotherapy, behavioural support and surgical intervention. Lifestyle approaches centre on dietary change and increased physical activity, yet physiological adaptations—altered appetite hormones, energy homoeostasis shifts and environmental pressures—often drive weight regain. Behavioural programmes leverage self-monitoring, goal setting and autonomous motivation to sustain change. Pharmacotherapeutic advances, notably glucagon-like peptide-1 receptor agonists and dual incretin agonists, enhance satiety and induce greater weight loss than lifestyle measures alone. In primary care, brief opportunistic advice with referral pathways into community or commercial weight-management groups has demonstrated modest population-level benefits. Digital health interventions offer scalable, low-cost support, though long-term engagement remains a challenge. Surgical procedures remain the most effective for substantial and durable weight reductions but carry higher risk and resource demands. An integrated model—tailoring interventions to individual risk profiles, preferences and comorbidities—optimises outcomes. Continued research into behavioural mediators, novel pharmacological targets and delivery modalities is vital to translate mechanistic insights into practical, cost-effective programmes that can be implemented at scale.

Research from Nature Portfolio

Recent studies have shown that dual agonists of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors markedly enhance weight loss when added to lifestyle intervention. In a large, placebo-controlled phase 3 trial, participants who sustained an initial 5 % weight reduction through intensive lifestyle change then received a weekly dual incretin agonist for 72 weeks. Treated individuals achieved a further mean weight loss of 18 %, with nearly nine in ten attaining at least an additional 5 % reduction. Gastrointestinal effects were the most common adverse events but were predominantly mild or moderate. These findings underscore the potential of novel multimodal therapies to transform long-term weight management in obesity without compromising safety.

Weight Management Strategies in Obesity and Diabetes publication trend

The graph below shows the total number of articles in weight management strategies in obesity and diabetes across all publications each year (not limited to Nature Index journals).

Technical terms

Body mass index (BMI): A standardised measure of adiposity calculated as body weight (kg) divided by height squared (m²), used to categorise underweight, healthy weight, overweight and obesity.

Glucagon-like peptide-1 (GLP-1) receptor agonist: A class of medications that mimic an incretin hormone to slow gastric emptying, suppress appetite and stimulate insulin secretion.

Dual incretin agonist: A therapeutic agent activating both GLP-1 and glucose-dependent insulinotropic polypeptide receptors to amplify weight-loss and glycaemic benefits.

Lifestyle intervention: A structured programme of dietary modification and physical activity designed to achieve weight reduction and improve metabolic health.

Self-regulation: The capacity to monitor and adjust behaviours—such as food intake and exercise—through goal setting, self-monitoring and coping strategies to support weight control.

References

1. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine (2023).
2. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. The BMJ (2014).
3. Successful behavior change in obesity interventions in adults: a systematic review of self-regulation mediators. BMC Medicine (2015).
4. Physiological adaptations to weight loss and factors favouring weight regain. International Journal of Obesity (2015).
5. Screening and brief intervention for obesity in primary care: a parallel, two-arm, randomised trial. The Lancet (2016).
6. Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial. The Lancet (2017).
7. Web-Based Digital Health Interventions for Weight Loss and Lifestyle Habit Changes in Overweight and Obese Adults: Systematic Review and Meta-Analysis. Journal of Medical Internet Research (2019).